# PDUFA dates April 2028: FDA calendar and catalysts

Canonical: https://sec-api.dev/fda-calendar/2028-04

> 20 FDA catalysts are dated in April 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## All catalysts in April 2028

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| April 2028 | [Aln-agt01 rvr primary completion](https://sec-api.dev/pdufa/aln-agt01-rvr) | ALNY | Hypertension | scheduled | "NCT07553442 (A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-04-01 (ESTIMATED); Lead Sponsor Alnylam Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07553442)) |
| April 2028 | [Gemzar (gemcitabine) primary completion](https://sec-api.dev/pdufa/gemcitabine) | JNJ | Non-Muscle Invasive Bladder Neoplasms | scheduled | "NCT06919965 (A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04-06 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06919965)) |
| April 2028 | [Elecoglipron primary completion](https://sec-api.dev/pdufa/elecoglipron) | AZN | Obesity; Overweight | scheduled | "NCT07775404 (A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04-06 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07775404)) |
| April 2028 | [Cilta-cel primary completion](https://sec-api.dev/pdufa/cilta-cel) | JNJ | Multiple Myeloma | scheduled | "NCT07149857 (A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-04-12 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07149857)) |
| April 2028 | [Vanrafia® (atrasentan) primary completion](https://sec-api.dev/pdufa/atrasentan) | NVS | IgA Nephropathy; Immunoglobulin A Nephropathy | scheduled | "NCT04573478 (Atrasentan in Patients With IgA Nephropathy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-04-14 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04573478)) |
| April 2028 | [Bivamelagon primary completion](https://sec-api.dev/pdufa/bivamelagon) | RYTM | Hypothalamic Obesity | scheduled | "NCT07156578 (A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2028-04-15 (ESTIMATED); Lead Sponsor Rhythm Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07156578)) |
| April 2028 | [Tacabrutideg primary completion](https://sec-api.dev/pdufa/tacabrutideg) | ONC | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | scheduled | "NCT06973187 (A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04-17 (ESTIMATED); Lead Sponsor BeOne Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06973187)) |
| April 2028 | [AMGEN INC primary completion](https://sec-api.dev/companies/amgn/catalysts) | AMGN | Osteogenesis Imperfecta | scheduled | "NCT07366086 (Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04-19 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07366086)) |
| April 2028 | [Surovatamig primary completion](https://sec-api.dev/pdufa/surovatamig) | AZN | B-cell Non-Hodgkin Lymphoma; Follicular Lymphoma (FL); Large B-Cell Lymphoma (LBCL) | scheduled | "NCT06526793 (Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-04-21 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06526793)) |
| April 2028 | [Golcadomide primary completion](https://sec-api.dev/pdufa/golcadomide) | BMY | Follicular Lymphoma | scheduled | "NCT06911502 (A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04-24 (ESTIMATED); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06911502)) |
| April 2028 | [AAA617 primary completion](https://sec-api.dev/pdufa/aaa617) | NVS | Oligometastatic Prostate Cancer (OMPC) | scheduled | "NCT05939414 (An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04-25 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05939414)) |
| April 2028 | [Litfulo (ritlecitinib tosylate) primary completion](https://sec-api.dev/pdufa/ritlecitinib) | PFE | Alopecia Areata | scheduled | "NCT07733765 (A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04-26 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07733765)) |
| April 2028 | [Aln-hsd primary completion](https://sec-api.dev/pdufa/aln-hsd) | REGN | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | scheduled | "NCT05519475 (A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-04-27 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05519475)) |
| April 2028 | [Low dose of ints-tcv primary completion](https://sec-api.dev/pdufa/low-dose-of-ints-tcv) | GSK | Salmonella Infections | scheduled | "NCT07286370 (A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-04-27 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07286370)) |
| April 2028 | [Roflumilast cream 0.3% primary completion](https://sec-api.dev/pdufa/roflumilast-cream-0-3) | ARQT | Atopic Dermatitis; Atopic Dermatitis (AD); Atopic Dermatitis (Eczema) | scheduled | "NCT07916480 (Roflumilast Cream 0.3% for Moderate to Severe Atopic Dermatitis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04-27 (ESTIMATED); Lead Sponsor Arcutis Biotherapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07916480)) |
| April 2028 | [Ziihera® (zanidatamab) primary completion](https://sec-api.dev/pdufa/zanidatamab) | JAZZ | Metastatic HER2-positive Breast Cancer | scheduled | "NCT06435429 (A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04-28 (ESTIMATED); Lead Sponsor Jazz Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06435429)) |
| April 2028 | [Zovegalisib primary completion](https://sec-api.dev/pdufa/zovegalisib) | RLAY | PIK3CA Mutation; HER2- Negative Breast Cancer; Hormone Receptor Positive Tumor | scheduled | "NCT06982521 (Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04-30 (ESTIMATED); Lead Sponsor Relay Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06982521)) |
| April 2028 | [RGX-121-3102 primary completion](https://sec-api.dev/pdufa/rgx-121-3102) | RGNX | MPS II; Hunter Syndrome (MPS II) | scheduled | "NCT07236606 (RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-04-30 (ESTIMATED); Lead Sponsor REGENXBIO Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07236606)) |
| April 2028 | [HMPL-760 primary completion](https://sec-api.dev/pdufa/hmpl-760) | HCM | Relapsed/Refractory Diffuse Large B-Cell Lymphoma | scheduled | "NCT07409428 (A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04-30 (ESTIMATED); Lead Sponsor Hutchmed." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07409428)) |
| April 2028 | [Berobenatide primary completion](https://sec-api.dev/pdufa/berobenatide) | PFE | Apnea; Sleep Disorders; Overweight and/or Obesity | scheduled | "NCT07823608 (A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Use a Breathing Machine (PAP) (VESPER-OSA 1)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04-30 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07823608)) |

Other months: https://sec-api.dev/fda-calendar/2028-03 , https://sec-api.dev/fda-calendar/2028-05. Calendar: https://sec-api.dev/fda-calendar

## Feeds and downloads

- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PDUFA dates April 2028: FDA calendar and catalysts." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/fda-calendar/2028-04

```bibtex
@misc{secapidev_fda_calendar_2028_04_20261116,
  title        = {PDUFA dates April 2028: FDA calendar and catalysts},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/fda-calendar/2028-04}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_fda_calendar_2028_04_20261116","title":"PDUFA dates April 2028: FDA calendar and catalysts","publisher":"sec-api.dev","URL":"https://sec-api.dev/fda-calendar/2028-04","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
